Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres

Recently, JM045 sustained-release microspheres, independently developed by the Institute of Innovative Pharmaceuticals under Jemincare Pharmaceutical Group, received clinical trial approval.

Medicilon, as a trusted partner, provided pharmacokinetic studies and GLP-compliant safety evaluations, playing an instrumental role in advancing the drug development process.

JM045: A New Hope for Prostate Cancer Patients

JM045 is a gonadotropin-releasing hormone (GnRH) analog with a novel mechanism designed to offer a better therapeutic option for prostate cancer patients in need of androgen deprivation therapy. It initially stimulates the pituitary gland to release gonadotropins, causing a transient rise in testosterone levels. However, continuous occupancy and downregulation of GnRH receptors suppress the secretion of LH and FSH, ultimately reducing testosterone production to castration levels.

This clinical approval represents a major step forward in oncology for Jemincare's Institute of Innovative Pharmaceuticals and another success for Medicilon, further establishing our expertise in preclinical drug development.

Medicilon: An Comprehensive Preclinical Drug Development Platform

With two decades of experience, Medicilon has honed its technical capabilities and continuously innovated to provide one-stop preclinical drug development services. From compound synthesis and activity screening to pharmacodynamics, pharmacokinetics, and GLP-compliant safety evaluations, Medicilon covers the full spectrum of preclinical research.

As of June 2024, Medicilon has contributed to the clinical approval of 490 new and generic drug projects, further cementing its role as a key partner in the global pharmaceutical industry.

Looking Ahead

Medicilon extends its congratulations to Jemincare's Institute of Innovative Pharmaceuticals on the clinical trial approval of JM045 and looks forward to the progress of further clinical trials. By iterating its comprehensive preclinical platform, Medicilon is committed to accelerating the journey of innovative drugs to clinical stages and improving therapeutic outcomes for prostate cancer patients and beyond.

About Jemincare Pharmaceutical Group

Founded in 1999 and headquartered in Nanchang, China, Jemincare focuses on nephrology, oncology, cardiovascular, respiratory anti-infective, and pain management. As a leading modern pharmaceutical group in China, Jemincare has consistently ranked among the top 10 in China's pharmaceutical industry for years.

About Medicilon

Established in 2004 and headquartered in Shanghai, Medicilon (Stock Code: 688202.SH) provides end-to-end preclinical drug development services to global pharmaceutical companies, research institutions, and scientists. With its efficient, cost-effective solutions and strong project management, Medicilon has served over 2,000 global clients, contributing to 490 IND approvals for new and generic drugs. The company continues to drive innovation from a global perspective while focusing on China's advancements, making significant contributions to human health.

Contact Us